Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion

99
15
Favorite

Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion

Bloomberg2021-08-23

Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion. Pfizer...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（15）

RO8
·2021-08-25
Good buy good buy
Reply
1
Report
Mml
·2021-08-24
Informative
Reply
3
Report
Lhgoh
·2021-08-23
Not bad
Reply
3
Report
Fold Replies
- huilly:
  wow..
  2021-08-23
  Reply
  Report
- JackTL:
  is good news
  2021-08-23
  Reply
  Report
HENRYCSC
·2021-08-23
Advance
Reply
2
Report
Gummybear
·2021-08-23
Power
Reply
3
Report
Sriwonc
·2021-08-23
Like
Reply
3
Report
Fold Replies
- K20:
  like
  2021-08-23
  Reply
  Report
Huat1333
·2021-08-23
Wow....[強] [強] [強]
Reply
3
Report
jyt20275
·2021-08-23
Good news
Reply
3
Report
Horsesaylah
·2021-08-23
??
Reply
3
Report
KenT
·2021-08-23
D
Reply
4
Report
jktrade
·2021-08-23
Hmm...
Reply
5
Report
PhilipGoh
·2021-08-23
Good
Reply
3
Report
jingabel
·2021-08-23
Ok
Reply
2
Report
Yappydappy
·2021-08-23
Is it going to soar now?
Reply
2
Report
Fold Replies
- SARA_231:
  yes!
  2021-08-23
  Reply
  Report
Korimerla
·2021-08-23
Noted
Reply
2
Report
Fold Replies
- Korimerla:
  ok
  2021-08-23
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1140755633?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-08-23 19:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140755633","market":"us","top_or_hot":-1,"title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","media":"Bloomberg","content":"<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Source Link</a>\n\n</div>\n","source":"lsy1584095487587","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PFE","symbol_name":"辉瑞","start_time":0,"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","article_id":"1140755633","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","pubTimestamp":1629717900,"sourceInfo":{"source_id":"lsy1584095487587","name":"Bloomberg"},"weMediaInfo":null,"summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","collect":0,"end_time":0,"defaultTopTitle":"bloomberg.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PFE":"辉瑞","TRIL":"Trillium Therapeutics Inc."},"translate_title":"辉瑞将以23亿美元收购癌症制药商延龄草","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":0.9,"TRIL":0.9},"content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":837000432,"gmtCreate":1629845584626,"gmtModify":1676530146668,"author":{"id":"3585981947031986","authorId":"3585981947031986","name":"RO8","avatar":"https://static.tigerbbs.com/1f744cb66900b3865c3ed1da7364ddce","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3585981947031986","authorIdStr":"3585981947031986"},"htmlText":"Good buy good buy","listText":"Good buy good buy","text":"Good buy good buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/837000432","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","kind":"news","pubTimestamp":1629717900,"share":"https://ttm.financial/m/news/1140755633?lang=&edition=fundamental","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","TRIL":"Trillium Therapeutics Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":834237694,"gmtCreate":1629805615318,"gmtModify":1676530136509,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3584863771682470","authorIdStr":"3584863771682470"},"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/834237694","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","kind":"news","pubTimestamp":1629717900,"share":"https://ttm.financial/m/news/1140755633?lang=&edition=fundamental","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","TRIL":"Trillium Therapeutics Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":835261682,"gmtCreate":1629721420846,"gmtModify":1676530110777,"author":{"id":"3583662534350147","authorId":"3583662534350147","name":"Lhgoh","avatar":"https://static.tigerbbs.com/1c2aee9a5977b03cf1fb62e2691c9aee","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583662534350147","authorIdStr":"3583662534350147"},"htmlText":"Not bad","listText":"Not bad","text":"Not bad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/835261682","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","kind":"news","pubTimestamp":1629717900,"share":"https://ttm.financial/m/news/1140755633?lang=&edition=fundamental","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","TRIL":"Trillium Therapeutics Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5622090,"gmtCreate":1629723993951,"gmtModify":1663232797531,"authorId":3584235357352543,"author":{"id":3584235357352543,"idStr":"3584235357352543","authorId":3584235357352543,"name":"huilly","avatar":"https://static.itradeup.com/news/b7a1fde5f6063db10091e669c2cc21f3","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":835261682,"type":1,"supId":5621953,"prevId":0,"content":"wow..","text":"wow..","html":"wow.."},{"id":5621953,"gmtCreate":1629723197658,"gmtModify":1663232795843,"authorId":3581557493426416,"author":{"id":3581557493426416,"idStr":"3581557493426416","authorId":3581557493426416,"name":"JackTL","avatar":"https://static.tigerbbs.com/851801800e7dc3457e5e60048a987880","vip":1,"currentWearingBadge":{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1102},"crmLevel":4,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":835261682,"type":1,"supId":0,"prevId":0,"content":"is good news","text":"is good news","html":"is good news"}],"langContent":"EN"},{"id":835263352,"gmtCreate":1629721296076,"gmtModify":1676530110746,"author":{"id":"3575091428590185","authorId":"3575091428590185","name":"HENRYCSC","avatar":"https://static.tigerbbs.com/6d47a6dec25b21dc547a5b982674c499","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575091428590185","authorIdStr":"3575091428590185"},"htmlText":"Advance&nbsp;","listText":"Advance&nbsp;","text":"Advance","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/835263352","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","kind":"news","pubTimestamp":1629717900,"share":"https://ttm.financial/m/news/1140755633?lang=&edition=fundamental","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","TRIL":"Trillium Therapeutics Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":835287126,"gmtCreate":1629720998865,"gmtModify":1676530110667,"author":{"id":"3581807556130510","authorId":"3581807556130510","name":"Gummybear","avatar":"https://static.tigerbbs.com/d2911351e3538d3ec7f08d283fb4ccfe","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581807556130510","authorIdStr":"3581807556130510"},"htmlText":"Power","listText":"Power","text":"Power","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/835287126","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","kind":"news","pubTimestamp":1629717900,"share":"https://ttm.financial/m/news/1140755633?lang=&edition=fundamental","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","TRIL":"Trillium Therapeutics Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":835212270,"gmtCreate":1629720201790,"gmtModify":1676530110290,"author":{"id":"3586424409701165","authorId":"3586424409701165","name":"Sriwonc","avatar":"https://static.tigerbbs.com/264a5cfcdc2db585d9b139a4c4d7b11d","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":6,"crmLevelSwitch":1,"idStr":"3586424409701165","authorIdStr":"3586424409701165"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/835212270","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","kind":"news","pubTimestamp":1629717900,"share":"https://ttm.financial/m/news/1140755633?lang=&edition=fundamental","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","TRIL":"Trillium Therapeutics Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5622079,"gmtCreate":1629723914574,"gmtModify":1663232796830,"authorId":3583284147557843,"author":{"id":3583284147557843,"idStr":"3583284147557843","authorId":3583284147557843,"name":"K20","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.68%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":835212270,"type":1,"supId":0,"prevId":0,"content":"like","text":"like","html":"like"}],"langContent":"EN"},{"id":835232266,"gmtCreate":1629719587655,"gmtModify":1676530110047,"author":{"id":"3559014783889591","authorId":"3559014783889591","name":"Huat1333","avatar":"https://community-static.tradeup.com/news/a4c138e1ce20043d7996468a91a225ac","vip":1,"hat":"https://static.tigerbbs.com/50a4c8d97279fa9f8f1fa9749a6bdff4","crmLevel":7,"crmLevelSwitch":1,"idStr":"3559014783889591","authorIdStr":"3559014783889591"},"htmlText":"Wow....[強]&nbsp;[強]&nbsp;[強]&nbsp;","listText":"Wow....[強]&nbsp;[強]&nbsp;[強]&nbsp;","text":"Wow....[強] [強] [強]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/835232266","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","kind":"news","pubTimestamp":1629717900,"share":"https://ttm.financial/m/news/1140755633?lang=&edition=fundamental","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","TRIL":"Trillium Therapeutics Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":835232898,"gmtCreate":1629719550714,"gmtModify":1676530110055,"author":{"id":"3581983450078020","authorId":"3581983450078020","name":"jyt20275","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581983450078020","authorIdStr":"3581983450078020"},"htmlText":"Good news","listText":"Good news","text":"Good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/835232898","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","kind":"news","pubTimestamp":1629717900,"share":"https://ttm.financial/m/news/1140755633?lang=&edition=fundamental","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","TRIL":"Trillium Therapeutics Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":835230223,"gmtCreate":1629718952062,"gmtModify":1676530109923,"author":{"id":"3570240810344953","authorId":"3570240810344953","name":"Horsesaylah","avatar":"https://static.tigerbbs.com/7a32990d23360f1c603728cf63a7ec50","vip":1,"hat":"https://static.tigerbbs.com/7b75ce0c34afff716602792a5d0929dd","crmLevel":2,"crmLevelSwitch":0,"idStr":"3570240810344953","authorIdStr":"3570240810344953"},"htmlText":"??","listText":"??","text":"??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/835230223","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","kind":"news","pubTimestamp":1629717900,"share":"https://ttm.financial/m/news/1140755633?lang=&edition=fundamental","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","TRIL":"Trillium Therapeutics Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":835296482,"gmtCreate":1629718507446,"gmtModify":1676530109743,"author":{"id":"3580341419226466","authorId":"3580341419226466","name":"KenT","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3580341419226466","authorIdStr":"3580341419226466"},"htmlText":"D","listText":"D","text":"D","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/835296482","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","kind":"news","pubTimestamp":1629717900,"share":"https://ttm.financial/m/news/1140755633?lang=&edition=fundamental","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","TRIL":"Trillium Therapeutics Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":835298374,"gmtCreate":1629718353598,"gmtModify":1676530109703,"author":{"id":"4087905137947130","authorId":"4087905137947130","name":"jktrade","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"4087905137947130","authorIdStr":"4087905137947130"},"htmlText":"Hmm...","listText":"Hmm...","text":"Hmm...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/835298374","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","kind":"news","pubTimestamp":1629717900,"share":"https://ttm.financial/m/news/1140755633?lang=&edition=fundamental","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","TRIL":"Trillium Therapeutics Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":835293459,"gmtCreate":1629718229871,"gmtModify":1676530109672,"author":{"id":"3574730309796268","authorId":"3574730309796268","name":"PhilipGoh","avatar":"https://static.tigerbbs.com/d6085185a57dcb9a222e871338387428","vip":1,"hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","crmLevel":7,"crmLevelSwitch":1,"idStr":"3574730309796268","authorIdStr":"3574730309796268"},"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/835293459","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","kind":"news","pubTimestamp":1629717900,"share":"https://ttm.financial/m/news/1140755633?lang=&edition=fundamental","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","TRIL":"Trillium Therapeutics Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":835299645,"gmtCreate":1629718068387,"gmtModify":1676530109631,"author":{"id":"3579683280519440","authorId":"3579683280519440","name":"jingabel","avatar":"https://static.tigerbbs.com/5109716c64f0b691a5098e4d5397ffc2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579683280519440","authorIdStr":"3579683280519440"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/835299645","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","kind":"news","pubTimestamp":1629717900,"share":"https://ttm.financial/m/news/1140755633?lang=&edition=fundamental","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","TRIL":"Trillium Therapeutics Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":835290765,"gmtCreate":1629717995257,"gmtModify":1676530109624,"author":{"id":"3579410204959880","authorId":"3579410204959880","name":"Yappydappy","avatar":"https://static.tigerbbs.com/5b6252f503d56d09093797f9e318ebf9","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3579410204959880","authorIdStr":"3579410204959880"},"htmlText":"Is it going to soar now?&nbsp;","listText":"Is it going to soar now?&nbsp;","text":"Is it going to soar now?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/835290765","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","kind":"news","pubTimestamp":1629717900,"share":"https://ttm.financial/m/news/1140755633?lang=&edition=fundamental","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","TRIL":"Trillium Therapeutics Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5621097,"gmtCreate":1629718820427,"gmtModify":1663232792937,"authorId":3582880272972541,"author":{"id":3582880272972541,"idStr":"3582880272972541","authorId":3582880272972541,"name":"SARA_231","avatar":"https://static.tigerbbs.com/bd8d92b2f3729a7b1cddcc2e989397cc","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":835290765,"type":1,"supId":0,"prevId":0,"content":"yes!","text":"yes!","html":"yes!"}],"langContent":"EN"},{"id":835290832,"gmtCreate":1629717973726,"gmtModify":1676530109607,"author":{"id":"3566099162047280","authorId":"3566099162047280","name":"Korimerla","avatar":"https://static.tigerbbs.com/8b1e7ef47aacafc432f0fe3719112ea2","vip":1,"crmLevel":3,"crmLevelSwitch":1,"idStr":"3566099162047280","authorIdStr":"3566099162047280"},"htmlText":"Noted&nbsp;","listText":"Noted&nbsp;","text":"Noted","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/835290832","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","kind":"news","pubTimestamp":1629717900,"share":"https://ttm.financial/m/news/1140755633?lang=&edition=fundamental","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","TRIL":"Trillium Therapeutics Inc."},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5620968,"gmtCreate":1629717983042,"gmtModify":1663232793241,"authorId":3566099162047280,"author":{"id":3566099162047280,"idStr":"3566099162047280","authorId":3566099162047280,"name":"Korimerla","avatar":"https://static.tigerbbs.com/8b1e7ef47aacafc432f0fe3719112ea2","vip":1,"crmLevel":3,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":835290832,"type":1,"supId":0,"prevId":0,"content":"ok<br>","text":"ok<br>","html":"ok<br>"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":99,"commentSize":15,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}